‘Contaminating’ Fake Research; Oncologist Shortage Grows; You Don’t Bring Me Flowers

A growing problem with fake medical research papers has “contaminated” scientific literature and slowed legitimate research with lifesaving potential. (The Conversation)

Financial toxicity gets an in-depth review from multiple perspectives in JCO Oncology Practice.

The shortage of oncologists in the U.S. will reach 2,200 during 2025, according to a report by Medicus Healthcare Solutions.

Healthcare/wellness tops the list of “sneaky” expenses that often catch retirees by surprise. (AARP)

A form of CAR T-cell that is injected directly into a tumor cleared a dog of lymphoma and potentially could work in humans. (University of Missouri College of Veterinary Medicine)

The Justice Department charged an Arizona couple with conspiracy, fraud, and violation of the Food, Drug, and Cosmetic Act for allegedly promoting and billing consumers $300 for “full body scans” that use “smart chip technology” to diagnose cancer and other medical conditions.

After accumulating almost 50 FDA-approved indications, has the blockbuster cancer drug pembrolizumab (Keytruda) hit the wall in its quest to expand the drug’s use? (BioSpace)

You don’t bring me flowers: An oncologist shares her ambivalence about enforcing a hospital rule that prohibits fresh flowers in cancer patients’ rooms. (Journal of Clinical Oncology)

After an interim analysis revealed disappointing safety results, including at least one death, Cargo Therapeutics announced discontinuation of a phase II trial of its CAR T-cell therapy firicabtagene autoleucel, stating the results “do not support a competitive benefit-risk profile.”

An FDA safety announcement regarding labeling changes for the commonly used oncology drugs capecitabine and 5-fluorouracil highlights a risk of dihydropyrimidine dehydrogenase deficiency, which can lead to potentially life-threatening toxicities.

An updated analysis of a phase III trial showed that the PI3K inhibitor inavolisib (Itovebi), in combination with palbociclib (Ibrance) and fulvestrant, significantly improved overall survival in advanced PIK3CA-mutated hormone receptor-positive/HER2-negative breast cancer, Roche announced.

People who live in historically “redlined” neighborhoods — associated with mortgage denials based on racial demographics — have an increased risk of cancer death, even though the practice was outlawed decades ago. (Cancer)

Please enable JavaScript to view the

comments powered by Disqus.